Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

EU Citizens Spend Over $27 Billion a Year on Drugs: Report

By Drug Discovery Trends Editor | April 5, 2016

Europol Director Rob Wainwright addresses the media on the EU Drug Markets Report at EU Commission headquarters in Brussels on Tuesday, April 5, 2016. The European Union's illicit drugs market is changing, and the rate of change is being accelerated by globalization and technology, according to the 2016 EU Drug Markets Report, suggesting the market is also increasingly connected with organized crime groups and terrorism. (AP Photo/Geert Vanden Wijngaert)A European Union report says the bloc’s citizens spend over $27 billion on drugs and 1 percent of adults use cannabis on an almost daily basis.
 
Tuesday’s report said that 38 percent of the retail market for drugs was cannabis, accounting for some $10.6 billion in annual trade. Behind cannabis, heroin came in second with a value of $7.7 billion a year.
 
The report also said that the drug trade could be seen as a “gateway for radicalization,” with drug offenders pushed toward radical views in jail. EU officials hinted at some links between the trade and recent extremist attacks but Europol chief Rob Wainwright said there was no evidence yet of any direct link between the two.
 
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

TransCelerate CEO Janice Chang wants trials to become part of routine care
STEERLife’s FragMelt platform manufactures drugs with heat sensitive active ingredient 
S&P report highlights Big Pharma’s concentration risk amid pre-JPM deal flurry
Eli Lilly in the Drug Discovery & Development Pharma 50
Lilly Phase 3b trial shows roughly 40-fold higher combined arthritis and weight-loss response
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE